Access brought to you by: LOCKSS
Login
Design of the STaR Trial
ARV, antiretroviral; EFV, efavirenz; FTC, emtricitabine; RPV, rilpivirine; STaR, single-tablet regimen; TDF, tenofovir.
Reproduced with permission from C Cohen, MD, MSc.
Virologic Outcomes and CD4 Change at Weeks 48 and 96
ARV, antiretroviral; EFV, efavirenz; FTC, emtricitabine; RPV, rilpivirine; TDF, tenofovir; W, week.
Thank you for your interest in spreading the word on MD Conference Express.
NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.